Navigation Links
Agarose, Type C from Calbiochem
...pathic effect inhibition assays, also known as CPE...ue culture supernatents; serum from PK studies and... is defined as the quantity of interferon required... viral infection by 50%. All standards used in o...
Topoisomerase I from Invitrogen
... type I eukaryotic topoisomerase that removes both...lled right- and left-handed supercoils) from coval... covalently closed, circular DNA with fewer positi...se I does not absolutely require Mg 2+ to functio...
Eco RII (Bst NI) from Roche Applied Science
Biology Products:
(Date:12/1/2009)... speaking, ants have two different feeding strateg...vorous," meaning that they are generalist predator...their remains. Some, however, are "herbivorous". ...her, the bulk of their diets consist of plant-deri...ids produced by plants to attract ants, called ext...
(Date:12/1/2009)...elease is available in German . , Brown adipo...tains loads of mitochondria, miniature power stat...oing this, they normally generate a voltage simila... for cellular processes. However, the mitochondria...full steam ahead all the time. The energy released...
(Date:12/1/2009)...ILLE, Fla. Hit-and-run attacks by sharks can be s...prits by the unique chomp they put on their victim... and shark expert. , In a method analogous to an...entifications by precisely comparing shark bites t...id George Burgess, director of the International S...
Breaking Biology News(10 mins):Bacterial gut symbionts are tightly linked with the evolution of herbivory in ants 2Brown fat cells make 'spare tires' shrink 2New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 1CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 2CareFusion Launches New Brand Establishing Itself as an Industry Leader in Helping Hospitals Improve Patient Care and Safety 50517 3NEUTROGENA 28R 29 and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection 50514 1NEUTROGENA 28R 29 and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection 50514 2NEUTROGENA 28R 29 and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection 50514 3Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 1Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 2Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 3Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 5Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 6Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 7Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 8Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 9
...sts have invented the world,s smallest version of ...d other micro-organisms from several sides at once...you only see cells from one side, the top," says t... of biological sciences. "Not only can we see the ...mething biologists almost never see." , The resea...
...9) A major asthma discovery by a researcher at the...een licensed by MedImmune, a leading innovation-fo...diary of AstraZeneca PLC. MedImmune licensed the ... a potential biologics drug for treating asthma. ...clusive intellectual property rights to the discov...
...model could be used to predict an individual,s lif...ren,s Hospital Informatics Program (CHIP). Using g... researchers showed that their predictive model co...oembolic stroke -- the most common form of stroke ...rted in the March issue of Stroke . , "For compl...
Other Biology News:Vanderbilt scientists invent world's smallest periscopes 2Vanderbilt scientists invent world's smallest periscopes 3La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 2La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 3Predicting risk of stroke from one's genetic blueprint 2
(Date:12/2/2009)... SINGAPORE, Dec. 2 S*BIO Pte Ltd t...l JAK2 inhibitor, SB1518, at The American Society ...n New Orleans. ,, Data will be presented on the... trial of SB1518 detailing its safety, tolerabilit...ile in dose levels ranging from 100 to 600 mg. The...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world ...in turmoil and uncertainty is part of many,busines...ndustry has been,relatively immune to the economic.... , During the midst of the difficult tim...p; Johnson inaugurated an R&D center in Shangh...
(Date:12/1/2009)...E VILLAGE, Nev., Dec. 1 ...nnounced revenue guidance for the fourth quarter e...n, as compared with $69 million for the fourth qua...lts was the first of two installment payments of $...h quarter 2008 results was a one-time $1.8 million...
(Date:12/1/2009)...UTH, Mass., Dec. 1 Harvest Technol...y results from the company sponsored 60-patient cl...Center in Chennai, India using the company,s BMAC ...Critical Limb Ischemia (CLI). Sri Ramachandra Medi...ciated institution based in Chennai, India and one...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3